Epilepsy Research
Volume 87, Issue 1 , Pages 31-39 , November 2009

Antiepileptic drugs in epilepsy and other disorders—A population-based study of prescriptions

  • Cecilie Johannessen Landmark

      Affiliations

    • Department of Pharmacy, Faculty of Health Sciences, Oslo University College, Pilestredet 50, N-0167 Oslo, Norway
    • Corresponding Author InformationCorresponding author. Tel.: +47 22 45 23 60; fax: +47 22 45 23 35.
    • ,
  • Pål G. Larsson

      Affiliations

    • The National Center for Epilepsy, Sandvika, Norway
    • Division of Clinical Neuroscience, Rikshospitalet, Oslo University Hospital, Oslo, Norway
    • ,
  • Elisif Rytter

      Affiliations

    • The National Center for Epilepsy, Sandvika, Norway
    • Division of Clinical Neuroscience, Rikshospitalet, Oslo University Hospital, Oslo, Norway
    • ,
  • Svein I. Johannessen

      Affiliations

    • The National Center for Epilepsy, Sandvika, Norway
    • Division of Clinical Neuroscience, Rikshospitalet, Oslo University Hospital, Oslo, Norway
    • Department of Clinical Biochemistry, Rikshospitalet, Oslo University Hospital, Oslo, Norway

Received 23 March 2009 ,Revised 31 May 2009 ,Accepted 15 July 2009.

References 

  1. Anmann B, Grünze H, Vieta E, Trimble M. Antiepileptic drugs and mood stability. Clin. EEG Neurosci. 2007;38:116–123
  2. Bigal ME, Lipton RB, Cohen J, Silberstein SD. Epilepsy and migraine. Epilepsy Behav. 2003;4:S13–24
  3. Caplan R, Siddarth P, Gurbani S, Hanson R, Sankar R, Shields WD. Depression and anxiety disorders in pediatric epilepsy. Epilepsia. 2005;46(5):720–730
  4. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr. Serv. 1998;49(2):196–201
  5. Davis KL, Candrilli SD, Edin HM. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population. Epilepsia. 2008;49(3):446–454
  6. Demyttenaere K, Mesters P, Boulanger B, Dewe W, Delsemme MH, Gregoire J, et al. Adherence to treatment regimen in depressed patients treated with amitriptyline or fluoxetine. J. Affect. Disord. 2001;65(3):243–252
  7. D'Souza WJ, Fryer JL, Quinn SJ, Taylor BV, Ficker DM, O’Brien TJ, et al. The Tasmanian epilepsy register—a community-based cohort. Background and methodology for patient recruitment from the Australian national prescription database. Neuroepidemiology. 2007;29(3/4):255–263
  8. Engeland A, Bramness JG, Daltveit AK, Rønning M, Skurtveit S, Furu K. Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106,000 pregnancies in Norway 2004–2006. Br. J. Clin. Pharmacol. 2008;65(5):653–660
  9. Ettinger AB, Kustra RP, Hammer AE. Effect of lamotrigine on depressive symptoms in adult patients with epilepsy. Epilepsy Behav. 2007;10:148–154
  10. French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, et al. Efficacy and tolerability of the new antiepileptic drugs, I: treatment of new-onset epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia. 2004;45:401–409
  11. French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, et al. Efficacy and tolerability of the new antiepileptic drugs, II: treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia. 2004;45:410–423
  12. Freynhagen R, Grond S, Schüpfer G, Hagebeuker A, Schmelz M, Ziegler D, et al. Efficacy and safety of pregabalin in treatment refractory patients with various neuropathic pain entities in clinical routine. Int. J. Clin. Pract. 2007;61(12):1989–1996Erratum in: Epilepsia 2004, 45, 1299
  13. Fuller-Thomson E, Brennenstuhl S. The association between depression and epilepsy in a nationally representative sample. Epilepsia. 2008;[Epub ahead of print]
  14. Furu K. Establishment of the nationwide Norwegian Prescription Database (NorPD)—new opportunities for research in pharmacoepidemiology in Norway. Norwegian J. Epidemiol. 2008;18(2):129–136Available at: www.ub.ntnu.no/journals/norepid or www.doaj.org.
  15. Furu K, Skurtveit S, Langhammer A, Nafstad P. Use of anti-asthmatic medications as a proxy for prevalence of asthma in children and adolescents in Norway: a nationwide prescription database analysis. Eur. J. Clin. Pharmacol. 2007;63(7):693–698
  16. Gaudiano BA, Weinstock LM, Miller IW. Improving treatment adherence in bipolar disorder: a review of current psychosocial treatment efficacy and recommendations for future treatment development. Behav. Modif. 2008;32(3):267–301
  17. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br. J. Psychiatry. 2009;194(1):4–9
  18. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2006;47:1094–1120
  19. Hausken AM, Furu K, Skurtveit S, Engeland A, Bramness JG. Starting insomnia treatment: the use of benzodiazepines versus z-hypnotics. A prescription database study of predictors. Eur. J. Clin. Pharmacol. 2009;65(3):295–301
  20. Hedenrud T, Jonsson P, Linde M. Beliefs about medicines and adherence among Swedish migraineurs. Ann. Pharmacother. 2008;42(1):39–45
  21. Hsieh LP, Huang CY. Prevalence of treated epilepsy in western medicine among the adult population in Taiwan: a study conducted using antiepileptic drug prescription data. Epilepsy Res. 2008;80(2/3):114–118
  22. Hsieh LP, Huang CY. Antiepileptic drug utilization in Taiwan: analysis of prescription using National Health Insurance database. Epilepsy Res. 2009, January 8;[Epub ahead of print]
  23. Jobe PC. Affective disorder and epilepsy comorbidity: implications for development of treatments, preventions and diagnostic approaches. Clin. EEG Neurosci. 2004;35:53–68
  24. Johannessen SI, Johannessen Landmark C. Value of therapeutic drug montoring in epilepsy. Exp. Rev. Neurother. 2008;8(6):929–939
  25. Johannessen Landmark C. Targets for antiepileptic drugs in the synapse. Med. Sci. Monit. 2007;13(1):RA1–RA7
  26. Johannessen Landmark C. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs. 2008;22:27–47
  27. Johannessen Landmark C, Rytter E, Johannessen SI. Clinical use of antiepileptic drugs at a referral center for epilepsy. Seizure. 2007;16:356–364
  28. Kanner AM. Depression in epilepsy: a neurobiological perspective. Epilepsy Curr. 2005;5:21–27
  29. Mulleners WM, Chronicle EP. Anticonvulsants in migraine prophylaxis: a Cochrane review. Cephalalgia. 2008;28(6):585–597
  30. Muzina DJ, Elhaj O, Gajwani P, Gao K, Calabrese JR. Lamotrigine and antiepileptic drugs as mood stabilizers in bipolar disorder. Acta Psychiatr. Scand. 2005;111:21–28
  31. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol. 2003;2:347–356
  32. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol. 2003;2(8):473–481
  33. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br. J. Clin. Pharmacol. 2006;61(3):246–255
  34. Poston S, Dickson M, Johnsrud M, Rupnow MF, Gdovin JM, Bramley TJ, et al. Topiramate prescribing patterns among medicaid patients: diagnoses, comorbidities, and dosing. Clin. Ther. 2007;29(3):504–518
  35. Prueter C, Norra C. Mood disorders and their treatment in patients with epilepsy. J. Neuropsych. Clin. Neurosci. 2005;17:20–28
  36. Pugh MJ, Van Cott AC, Cramer JA, Knoefel JE, Amuan ME, Tabares J, et al. Treatment in Geriatric Epilepsy Research (TIGER) team, trends in antiepileptic drug prescribing for older patients with new-onset epilepsy: 2000–2004. Neurology. 2008;70(22):2171–2178
  37. Rochat P, Hallas J, Gaist D, Friis ML. Antiepileptic drug utilization: a Danish prescription database analysis. Acta Neurol. Scand. 2001;104:6–11
  38. Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat. Med. 2004;10:685–692
  39. Savica R, Beghi E, Mazzaglia G, Innocenti F, Brignoli O, Cricelli C, et al. Prescribing patterns of antiepileptic drugs in Italy: a nationwide population-based study in the years 2000–2005. Eur. J. Neurol. 2007;14(12):1317–1321Erratum in: Eur. J. Neurol. 2008, 15(3), 313
  40. Schmitz B. Depression and mania in patients with epilepsy. Epilepsia. 2005;46(Suppl. 4):45–49
  41. Silberstein SD. Shared mechanisms and comorbidities in neurologic and psychiatric disorders. Headache. 2001;41:S11–S17
  42. Silberstein SD, Neto W, Schmitt J, Jacobs D MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Arch. Neurol. 2004;61(4):490–495
  43. Skurtveit S, Furu K, Kaasa S, Borchgrevink PC. Introduction of low dose transdermal buprenorphine—did it influence use of potentially addictive drugs in chronic non-malignant pain patients?. Eur. J. Pain. 2008, December 16;[Epub ahead of print]
  44. Spina E, Perugi G. Antiepileptic drugs: indications other than epilepsy. Epileptic Disord. 2004;6:57–75
  45. Tassone DM, Boyce E, Guyer J, Nuzum D. Pregabalin: a novel γ-butyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin. Ther. 2007;29(1):26–48
  46. Tellez-Zenteno JF, Patten SB, Jetté N, Williams J, Wiebe S. Psychiatric comorbidity in epilepsy: a population based analysis. Epilepsia. 2007;48(12):2336–2344
  47. Thompson C, Peveler RC, Stephenson D, McKendrick J. Compliance with antidepressant medication in the treatment of major depressive disorder in primary care: a randomized comparison of fluoxetine and a tricyclic antidepressant. Am. J. Psychiatry. 2000;157(3):338–343
  48. Tsiropoulos B, Gichangi A, Andersen M, Bjerrum L, Gaist D, Hallas J. Trends in utilization of antiepileptic drugs in Denmark. Acta Neurol. Scand. 2006;113:405–411
  49. van de Vrie-Hoekstra NW, de Vries TW, van den Berg PB, Brouwer OF, de Jong-van den Berg LT. Antiepileptic drug utilization in children from 1997–2005—a study from The Netherlands. Eur. J. Clin. Pharmacol. 2008;64(10):1013–1020
  50. White HS. Molecular pharmacology of topiramate: managing seizures and preventing migraine. Headache. 2005;45:S48–56
  51. Zin CS, Nissen LM, Smith MT, O’Callaghan JP, Moore BJ. An update on the pharmacological management of post-herpetic neuralgia and painful diabetic neuropathy. CNS Drugs. 2008;22(5):417–442

PII: S0920-1211(09)00197-1

doi: 10.1016/j.eplepsyres.2009.07.005

Epilepsy Research
Volume 87, Issue 1 , Pages 31-39 , November 2009

Article Tools

* Image Usage & Resolution